Skip to main content
Top
Literature
1.
go back to reference Chatziralli I, Theodossiadis G, Kabanarou SA, Parikakis E, Xirou T, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-017-3719-5 Published online June 15, 2017 Chatziralli I, Theodossiadis G, Kabanarou SA, Parikakis E, Xirou T, Mitropoulos P, Theodossiadis P (2017) Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study. Graefes Arch Clin Exp Ophthalmol. doi:10.​1007/​s00417-017-3719-5 Published online June 15, 2017
2.
go back to reference Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMed Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMed
3.
go back to reference Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRef Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRef
4.
go back to reference Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to vcretinal vein occlusion. Retina 34:1743–1749CrossRefPubMed Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to vcretinal vein occlusion. Retina 34:1743–1749CrossRefPubMed
5.
go back to reference Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase lll study. Ophthalmology 118:2041–2049CrossRefPubMed Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase lll study. Ophthalmology 118:2041–2049CrossRefPubMed
6.
go back to reference Haller JA, Bandello F, RJr B, Blumenkranz MS, Gilles M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118(Ozurdex Geneva Study Group):2453–2560CrossRefPubMed Haller JA, Bandello F, RJr B, Blumenkranz MS, Gilles M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118(Ozurdex Geneva Study Group):2453–2560CrossRefPubMed
7.
go back to reference Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed
8.
go back to reference Călugăru D, Călugăru M (2017) Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye 31:1112–1113 Călugăru D, Călugăru M (2017) Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye 31:1112–1113
9.
go back to reference Călugăru D, Călugăru M (2017) Baseline choroidal thickness as a predictor for treatment oucomes in central retinal vein occlusion. Am J Ophthalmol 176:257–258PubMed Călugăru D, Călugăru M (2017) Baseline choroidal thickness as a predictor for treatment oucomes in central retinal vein occlusion. Am J Ophthalmol 176:257–258PubMed
10.
go back to reference Călugăru D, Călugăru M (2017) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255:427–428CrossRefPubMed Călugăru D, Călugăru M (2017) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255:427–428CrossRefPubMed
Metadata
Title
Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study
Authors
Dan Călugăru
Mihai Călugăru
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-017-3749-z

Other articles of this Issue 10/2017

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2017 Go to the issue